



Tango Therapeutics Announces Presentation of Preclinical Data on Lead Program and Discovery Platform in Five Abstracts Accepted at AACR-NCI-EORTC 2021

September 30, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 30, 2021-- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been selected for presentation as virtual posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 7 – 10, 2021.

"The preclinical data being presented today highlight the potential applicability of synthetic lethal drug targeting across a range of cancer types. As an example, our lead program, TNG908, an MTA-cooperative PRMT5 inhibitor selective for cancers with deletion of the MTAP gene, shows strong regressions across multiple types of cancer," said Barbara Weber, M.D., president and Chief Executive Officer of Tango Therapeutics. "We look forward to leveraging these data to inform our planned clinical development program."

Dr. Weber will also be co-chairing an Educational session titled "Exploiting Synthetic Lethality" on October 7, 2021 at 10:00 AM ET.

Details on Tango's presentations at AACR-NCI-EORTC are as follows:

Poster Title: MTAP^{null}-selective PRMT5 inhibitors drive regressions in MTAP-deleted xenograft models across histologies

Abstract #: P214

Date and Time: October 7, 9:00 AM ET

Poster Title: VRK1 is a novel synthetic lethal target in VRK2-methylated glioblastoma

Abstract #: P182

Date and Time: October 7, 9:00 AM ET

Poster Title: CRISPR screens identify sensitizers to Trametinib in KRAS mutant cancer cell lines

Abstract #: P183

Date and Time: October 7, 9:00 AM ET

Poster Title: Loss of HS2ST1 cooperates with MAPK inhibition to impair growth of mesenchymal KRAS mutant NSCLC

Abstract #: P146

Date and Time: October 7, 9:00 AM ET

Poster Title: Isogenic CRISPR Anchor Screens identified actionable nodes to CHK1/2 inhibitor Prexasertib in TP53 mutant cancer

Abstract #: P095

Date and Time: October 7, 9:00 AM ET

About Tango Therapeutics

Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangoqx.com.

Forward-Looking Statements

Certain statements in this press release and the posters referenced herein may be considered forward-looking statements. Forward-looking statements generally relate to future events, Tango's future operating performance, goals, expectations, beliefs and development objectives for Tango's product pipeline. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expect", "intend", "will", "goal", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. For example, statements concerning the following include or constitute forward-looking statements: the data presented highlights the potential applicability of synthetic lethal drug targeting across a range of approaches for the treatment of cancers; the potential benefits of the synthetic lethal approach to treating cancer; the Company will leverage these data to inform its planned clinical development program; Tango's ability to identify, develop and commercialize drug candidates; the future anticipated benefits of product candidates (including TNG908) identified through the Tango discovery platform; and the expected timing of: (i) development candidate declaration for certain targets, (ii) initiating IND-enabling studies; (iii) filing INDs and (iv) clinical trial initiation. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Tango and its management are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: Tango has a limited operating history and has not generated any revenue to date from drug sales, and may never become profitable; Tango will need to raise capital in the future and if we are unable to raise capital when needed or on attractive terms, we would be forced to delay, scale back or discontinue some of our development programs or future commercialization efforts; we may be unable to advance our preclinical development programs into and through the clinic for safety or efficacy reasons or commercialize our product candidates or we may experience significant delays in doing so as a result of factors beyond Tango's control; Tango's approach to the discovery and

development of product candidates is novel and unproven, which makes it difficult to predict the time, cost of development, and likelihood of successfully developing any products; Tango may not identify or discover additional product candidates or may expend limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success; our products candidates may cause adverse or other undesirable side effects that could, among other things, delay or prevent regulatory approval; our dependence on third parties for conducting clinical trials and producing drug product; our ability to obtain and maintain patent and other intellectual property protection for our technology and product candidates or the scope of intellectual property protection obtained is not sufficiently broad; and delays and other impacts on product development and clinical trials from the COVID-19 pandemic. Additional information concerning risks, uncertainties and assumptions can be found in Tango's filings with the SEC, including the risk factors referenced in Tango's Current Report on Form 8-K filed with the SEC on August 13, 2021. You should not place undue reliance on forward-looking statements in this presentation, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Tango specifically disclaims any duty to update these forward-looking statements.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210930005136/en/): <https://www.businesswire.com/news/home/20210930005136/en/>

Investor Contact:

Sam Martin
Argot Partners
tango@argotpartners.com

Media Contact:

Joshua R. Mansbach
Argot Partners
tango@argotpartners.com

Source: Tango Therapeutics, Inc.